Daniel Lavanchy
HCV disease burden and population segments in Switzerland
Bihl F, Semmo N, Semela D, Scheidegger C, Razavi H, Negro F, Mullhaupt B, Lavanchy D, Dufour J, Castro Batänjer E, Bruggmann P, Blach S. HCV disease burden and population segments in Switzerland. Liver Int 2021
27.11.2021HCV disease burden and population segments in Switzerland
27.11.2021Liver Int 2021
Bihl Florian, Semmo Nasser, Semela David, Scheidegger Claude, Razavi Homie, Negro Francesco, Mullhaupt Beat, Lavanchy Daniel, Dufour Jean-François, Castro Batänjer Erika, Bruggmann Philip, Blach Sarah
Progress toward implementing the Swiss Hepatitis Strategy: Is HCV elimination possible by 2030?
Mullhaupt B, Bruggmann P, Bihl F, Blach S, Lavanchy D, Razavi H, Robbins Scott S, Semela D, Negro F. Progress toward implementing the Swiss Hepatitis Strategy: Is HCV elimination possible by 2030?. PloS one 2018; 13:e0209374.
31.12.2018Progress toward implementing the Swiss Hepatitis Strategy: Is HCV elimination possible by 2030?
31.12.2018PloS one 2018; 13:e0209374
Mullhaupt Beat, Bruggmann Philip, Bihl Florian, Blach Sarah, Lavanchy Daniel, Razavi Homie, Robbins Scott Sarah, Semela David, Negro Francesco
Hepatitis C virus dynamics among intravenous drug users suggest that an annual treatment uptake above 10% would eliminate the disease by 2030
Bruggmann P, Stoeckle M, Semela D, Schmid P, Razavi H, Rauch A, Mullhaupt B, Lavanchy D, Kouyos R, Fehr J, Deltenre P, Blach S, Negro F. Hepatitis C virus dynamics among intravenous drug users suggest that an annual treatment uptake above 10% would eliminate the disease by 2030. Swiss Med Wkly 2017; 147:w14543.
09.11.2017Hepatitis C virus dynamics among intravenous drug users suggest that an annual treatment uptake above 10% would eliminate the disease by 2030
09.11.2017Swiss Med Wkly 2017; 147:w14543
Bruggmann Philip, Stoeckle Marcel, Semela David, Schmid Patrick, Razavi Homie, Rauch Andri, Mullhaupt Beat, Lavanchy Daniel, Kouyos Roger, Fehr Jan, Deltenre Pierre, Blach Sarah, Negro Franco
Birth cohort distribution and screening for viraemic hepatitis C virus infections in Switzerland
Bruggmann P, Negro F, Bihl F, Blach S, Lavanchy D, Mullhaupt B, Razavi H, Semela D. Birth cohort distribution and screening for viraemic hepatitis C virus infections in Switzerland. Swiss Med Wkly 2015; 145:w14221.
04.12.2015Birth cohort distribution and screening for viraemic hepatitis C virus infections in Switzerland
04.12.2015Swiss Med Wkly 2015; 145:w14221
Bruggmann Philip, Negro Francesco, Bihl Florian, Blach Sarah, Lavanchy Daniel, Mullhaupt Beat, Razavi Homie, Semela David
Modeling the Health and Economic Burden of Hepatitis C Virus in Switzerland
Mullhaupt B, Bruggmann P, Bihl F, Blach S, Lavanchy D, Razavi H, Semela D, Negro F. Modeling the Health and Economic Burden of Hepatitis C Virus in Switzerland. PloS one 2015; 10:e0125214.
24.06.2015Modeling the Health and Economic Burden of Hepatitis C Virus in Switzerland
24.06.2015PloS one 2015; 10:e0125214
Mullhaupt Beat, Bruggmann Philip, Bihl Florian, Blach Sarah, Lavanchy Daniel, Razavi Homie, Semela David, Negro Francesco